Tham khảo Talizumab

  1. 1 2 Pollack A. Wrangling May Delay Peanut Allergy Drug. New York Times March 13, 2003. https://www.nytimes.com/2003/03/13/business/wrangling-may-delay-peanut-allergy-drug.html?pagewanted=all&src=pm
  2. ↑ Hamilton DP. How Genentech, Novartis Stifled A Promising Drug. Wall Street Journal April 5, 2005. http://online.wsj.com/article/0,,SB111265511632497703-search,00.html
  3. ↑ “Trials of an allergy drug Remedy against peanuts is mired in legal battles - International Herald Tribune - HighBeam Research”. Bản gốc lưu trữ ngày 12 tháng 3 năm 2007. Truy cập ngày 19 tháng 3 năm 2008. 
  4. ↑ http://www.thefreelibrary.com/Court+Stays+Lawsuit+Against+Tanox,+Inc.%3B+Judge+Returns+Parties+to...-a080862592
  5. 1 2 Leung DY, Sampson HA, Yunginger JW và đồng nghiệp (2003). “Effect of anti-IgE therapy in patients with peanut allergy”. N. Engl. J. Med. 348 (11): 986–93. PMID 12637608. doi:10.1056/NEJMoa022613. 
  6. 1 2 Leung DY, Shanahan WR, Li XM, Sampson HA (2004). “New approaches for the treatment of anaphylaxis”. Novartis Found. Symp. Novartis Foundation Symposia 257: 248–60; discussion 260–4, 276–85. ISBN 978-0-470-86119-6. PMID 15025403. doi:10.1002/0470861193.ch20. 
  7. ↑ Delayed help for peanut allergy sufferers - A new drug has been shown to offer protection against this sometimes fatal malady. Further testing, however, is stuck in a legal limbo. Business Week March 10, 2003. http://www.businessweek.com/technology/content/mar2003/tc20030310_8777_tc024.htm
  8. ↑ Robbins-Roth C. A David Vs. Goliath Biotech Story, With Goliath Winning. BioWorld Today April 8, 2005. http://www.bioventureconsultants.com/4-8-05_Article.html
  9. ↑ Sampson HA, Leung DY, Burks AW, Lack G, Bahna SL, Jones SM, Wong DA (tháng 3 năm 2011). “A phase II, randomized, double blind, parallel group, placebo controlled oral food challenge trial of Xolair (omalizumab) in peanut allergy”. J. Allergy Clin. Immunol. 127 (5): 1309–10.e1. PMID 21397314. doi:10.1016/j.jaci.2011.01.051. 
  10. ↑ Chang TW, Davis FM, Sun NC, Sun CR, MacGlashan DW J, Hamilton RG (tháng 2 năm 1990). “Monoclonal antibodies specific for human IgE-producing B cells: a potential therapeutic for IgE-mediated allergic diseases”. Bio/Technology 8 (2): 122–6. PMID 1369991. doi:10.1038/nbt0290-122.  Lỗi văn phong Vancouver (trợ giúp)
  11. ↑ Chang TW (tháng 2 năm 2000). “The pharmacological basis of anti-IgE therapy”. Nat. Biotechnol. 18 (2): 157–62. PMID 10657120. doi:10.1038/72601. 
  12. ↑ Chang TW, Wu PC, Hsu CL, Hung AF (2007). “Anti-IgE antibodies for the treatment of IgE-mediated allergic diseases”. Adv Immunol. 93: 63–119. PMID 17383539. doi:10.1016/S0065-2776(06)93002-8. 
  13. ↑ Corne J, Djukanovic R, Thomas L, Warner J, Botta L, Grandordy B, Gygax D, Heusser C, Patalano F, Richardson W, Kilchherr E, Staehelin T, Davis F, Gordon W, Sun L, Liou R, Wang G, Chang TW, Holgate S (tháng 3 năm 1997). “The effect of intravenous administration of a chimeric anti-IgE antibody on serum IgE levels in atopic subjects: efficacy, safety, and pharmacokinetics”. J Clin Invest 99 (5): 879–87. PMC 507895. PMID 9062345. doi:10.1172/JCI119252. 
  14. ↑ Racine-Poon A, Botta L, Chang TW, Davis FM, Gygax D, Liou RS, Rohane P, Staehelin T, van Steijn AM, Frank W (tháng 12 năm 1997). “Efficacy, pharmacodynamics, and pharmacokinetics of CGP 51901, an anti-immunoglobulin E chimeric monoclonal antibody, in patients with seasonal allergic rhinitis”. Clin Pharmacol Ther 62 (6): 675–90. PMID 9433396. doi:10.1016/S0009-9236(97)90087-4. 

Tài liệu tham khảo

WikiPedia: Talizumab http://www.bioventureconsultants.com/4-8-05_Articl... http://www.businessweek.com/technology/content/mar... http://www.highbeam.com/doc/1P1-72561487.html http://www.thefreelibrary.com/Court+Stays+Lawsuit+... http://online.wsj.com/article/0,,SB111265511632497... //www.ncbi.nlm.nih.gov/pmc/articles/PMC507895 //www.ncbi.nlm.nih.gov/pubmed/10657120 //www.ncbi.nlm.nih.gov/pubmed/12637608 //www.ncbi.nlm.nih.gov/pubmed/1369991 //www.ncbi.nlm.nih.gov/pubmed/15025403